A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer

Trial Profile

A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Hyaluronidase (Primary) ; Atezolizumab
  • Indications Gastric cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 24 Oct 2017 According to a Halozyme Therapeutics media release, the study will be conducted in the U.S., as well as countries outside the U.S. The overall analysis plan includes a retrospective analysis of the HA-high population identified using the Ventana HA companion diagnostic assay.
    • 24 Oct 2017 According to a Halozyme Therapeutics media release, first gastric cancer patient has been dosed in the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top